XENE - Xenon Pharmaceuticals Inc Stock Price, Fair Value and News

43.96USD+0.11 (+0.25%)Market Closed

Market Summary

USD43.96+0.11

Market Closed

0.25%

XENE Stock Price

View Fullscreen

XENE RSI Chart

XENE Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-17.55

Price/Sales (Trailing)

340.07

EV/EBITDA

-17.57

Price/Free Cashflow

-20.99

XENE Price/Sales (Trailing)

XENE Profitability

EBT Margin

-2000.92%

Return on Equity

-21.25%

Return on Assets

-20.52%

Free Cashflow Yield

-4.77%

XENE Fundamentals

XENE Revenue

Revenue (TTM)

9.4M

XENE Earnings

Earnings (TTM)

-188.6M

Earnings Growth (Yr)

-14.87%

Earnings Growth (Qtr)

-7.13%

Breaking Down XENE Revenue

Last 7 days

5.3%

Last 30 days

18.5%

Last 90 days

8.3%

Trailing 12 Months

22.5%

How does XENE drawdown profile look like?

XENE Financial Health

Current Ratio

31.82

Debt/Equity

0.01

Debt/Cashflow

-14.15

XENE Investor Care

Shares Dilution (1Y)

18.73%

Diluted EPS (TTM)

-2.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	22.8M	21.2M	13.2M	9.4M
2021	29.4M	18.3M	19.9M	18.4M
2020	13.9M	27.3M	30.3M	32.2M
2019	0	0	4.2M	7.1M
2017	0	0	1.5M	1.1M
2016	12.2M	8.5M	4.7M	1.8M
2015	27.4M	26.1M	17.2M	15.6M
2014	27.0M	26.7M	29.1M	28.4M
2013	17.6M	20.8M	24.1M	27.4M
2012	0	0	0	14.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

CEO	Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
WEBSITE	xenon-pharma.com
INDUSTRY	Biotechnology
EMPLOYEES	203

Xenon Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Xenon Pharmaceuticals Inc? What does XENE stand for in stocks?

XENE is the stock ticker symbol of Xenon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xenon Pharmaceuticals Inc (XENE)?

As of Thu Jul 25 2024, market cap of Xenon Pharmaceuticals Inc is 3.31 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XENE stock?

You can check XENE's fair value in chart for subscribers.

Is Xenon Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XENE is over valued or under valued. Whether Xenon Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Xenon Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XENE.

What is Xenon Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, XENE's PE ratio (Price to Earnings) is -17.55 and Price to Sales (PS) ratio is 340.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XENE PE ratio will change depending on the future growth rate expectations of investors.